Incidence and Treatment of Hyperlipidemia in Primary and Secondary Adrenal Insufficiency

  • K. Ehlenz
  • J. Steinseifer
  • H. Kaffarnik
  • A. Steinmetz
Conference paper
Part of the Recent Developments in Lipid and Lipoprotein Research book series (LIPID)

Summary

Although hyperlipidemia occuring in hypopituitarism has been known for a long time, only sporadic reports are available. Recently a survey on 333 patients with hypopituitarism reported a shortened life expectancy in these patients mainly because of vascular disorders. As hyperlipidemia is a major risk factor for vascular disease we investigated the incidence of hyperlipidemia in 23 patients with primary and 35 patients with secondary (due to diseases of the pituitary gland) adrenal insufficiency. All patients had been substituted for deficient hormones according to generally accepted rules. Hypercholesterolemia was the dominant lipid disorder and plasma cholesterol levels above 250 mg/dl occured in more than 60% of the patients studied as compared to 20–30% reported in German and North American populations. 13 patients with severe hyperlipidemia consented to treatment with diet, colestipol or fenofibrate. They responded well and plasma lipid levels could be normalized. The high prevalence of hyperlipidemia may be one major factor for the diminished life expectancy in patients with hypopituitarism (and probably also with primary adrenal insufficiency) and should thus be treated, although the longterm benefit of treatment has not yet been established.

Keywords

Cholesterol Cortisol Electrophoresis Triglyceride Hypothyroidism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Assmann G, Schulte H (1992) Hyperlipidemia according to age. Excerpta Medica Tokio (in press).Google Scholar
  2. 2.
    Barrett-Conner E, Khaw KT, Yen SSC (1986) A prospective study of dehydro epiandrosterone sulfate, mortality, and cardiovascular disease. N Eng J Med 315, 24: 1519–1524.CrossRefGoogle Scholar
  3. 3.
    Blackett PR, Weech PK, McConathy WJ, Fesmire JD (1982) Growth hormone in the regulation of hyperlipidemia. Metabolism 31: 117–120.PubMedCrossRefGoogle Scholar
  4. 4.
    Conn JW, Vogel WC (1949) Effects of prolonged adrenal cortical stimulation upon free and esterified cholesterol in normal men. J Clin Endocrin 9: 656–660.Google Scholar
  5. 5.
    Essen von R (1992) Regression der Koronarsklerose durch Behandlung der Fettstoffwechselstörung? Erste klinische Ergebnisse und methodische Probleme. Internist 33: 62–66.Google Scholar
  6. 6.
    Fredrickson DS, Gordon RS Jr (1958) Transport of fatty acids. Phys Rev 38: 585–596.Google Scholar
  7. 7.
    Friedman M, Byers SO, Rosenman RH, Li CH, Neuman R (1974) Effect of sub acute administration of human growth hormone on various serum lipid and hormone levels of hypercholesteremic and normocholesterolemic subjects. Metabolism 23: 905–912.PubMedCrossRefGoogle Scholar
  8. 8.
    Havel RJ (1989) Biology of cholesterol, lipoproteins and atherosclerosis. Clin Exp Hyerth Pract A 11: 887–900.CrossRefGoogle Scholar
  9. 9.
    Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, Frantz ID Jr (1980) Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation 61,2: 302–315.PubMedGoogle Scholar
  10. 10.
    Ishibashi S, Murase T, Yamada N, Tanaka K, Takahu F, Sato K (1985) Hyperlipidaemia in patients with hypopituitarism. Acta Endocrinol 110: 456–460.PubMedGoogle Scholar
  11. 11.
    Jacobs RJ, Krieger DT, Charles RN (1961) Late appearance of hyperlipemia in hypopituitarism. Ann Int Med 55: 640–646.PubMedGoogle Scholar
  12. 12.
    Kask E (1959) 17-Ketosteroids and Arteriosclerosis. Angiology 10: 358–368.PubMedCrossRefGoogle Scholar
  13. 13.
    Kovanen PT, Goldstein JL, Chappell DA (1980) Regulation of low density lipoprotein receptors by adrenocorticotropin in the adrenal gland of mice and rats in vivo. J Biol Chem 255: 5591–5598.PubMedGoogle Scholar
  14. 14.
    Merimee T, Hollander W, Fineberg E (1972) Studies of hyperlipidemia in the hGH-deficient state. Metabolism 21: 1053–1061.PubMedCrossRefGoogle Scholar
  15. 15.
    Nestler JE, Barlascini CO, Clore JN, Blackard WG (1988) Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66: 57–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59: 551–555.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosén T, Bengtsson B-Å (1990) Premature mortality due to cardiovascular disease in hypopituitarism. The Lancet 336: 285–288.CrossRefGoogle Scholar
  18. 18.
    Salomon F, Cuneo RC, Hesp R, Sönksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321: 1797–1803.PubMedCrossRefGoogle Scholar
  19. 19.
    Steinmetz A, Karrarnik H (1992). Medikamentose Therapie der Hyperlipoproteinamien. Internist 33: 44–53.PubMedGoogle Scholar
  20. 20.
    Summers VK, Jipkin LJ, Davis JC (1967) Serum lipids in diseases of the pituitary. Metabolism 16, 12: 1106–1113.PubMedCrossRefGoogle Scholar
  21. 21.
    Thuesen L, Christiansen JS, Sorensen KE, Jorgensen JOL, Orskov H, Henningsen P (1988) Increased myocardial contractility following growth hormone administration in normal man. Dan Med Bull 351: 193–196.Google Scholar
  22. 22.
    Zöllner N (1955) Hypopituitarismus (Sheehansches Syndrom) mit Hyperlipamie und Xanthomen. Dt Med Wschr 80: 999–1002.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • K. Ehlenz
  • J. Steinseifer
  • H. Kaffarnik
  • A. Steinmetz

There are no affiliations available

Personalised recommendations